已发表论文

circ-SHPRH 对实体癌的诊断和预后作用:荟萃分析

 

Authors Li F, Huang Q, Gong Z, Wang H, Chen J

Received 8 January 2019

Accepted for publication 4 April 2019

Published 31 May 2019 Volume 2019:12 Pages 4351—4357

DOI https://doi.org/10.2147/OTT.S200755

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Ms Shreya Arora

Peer reviewer comments 3

Editor who approved publication: Dr William Cho

Background: Circ-SHPRH is a novel circular RNA which was down-regulated in various cancer tissues. Several recent studies hinted that circ-SHPRH might function as a diagnostic and prognostic biomarker for solid cancers. This meta-analysis was performed to determine the diagnostic and prognostic roles of circ-SHPRH for these solid cancers.
Methods: Publications were searched in PubMed, MEDLINE, Web of Science, Embase, China National Knowledge Infrastructure (CNKI), and Wanfang database. Pooled sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR), and area under the summary receiver operating characteristic curve (SROC) (AUC) with 95% confidence interval (95% CI) were calculated to evaluate the diagnostic value of circ-SHPRH. Pooled hazard ratio (HR) with 95% CI was applied to assess the prognostic value of circ-SHPRH.
Results: Nine eligible studies, including 4 for diagnosis and 5 for prognosis, were included in this meta-analysis. Pooled sensitivity, specificity, PLR, NLR, DOR, and AUC were 0.79 (95% CI: 0.73–0.84), 0.75 (95% CI: 0.69–0.81), 3.20 (95% CI: 2.53–4.06), 0.28 (95% CI: 0.22–0.36), 11.27 (95% CI: 7.57–16.79), and 0.84 (95% CI: 0.80–0.87), respectively. Pooled HR indicated that low circ-SHPRH expression was significantly associated with poor overall survival (OS) (low vs high, HR=2.22, 95% CI: 1.60–3.09).
Conclusion: The results of this meta-analysis indicate that circ-SHPRH might be an important diagnostic and prognostic biomarker for various solid cancers.
Keywords: Circ-SHPRH, diagnosis, prognosis, cancer, meta-analysis




Figure 2 Quality assessment of eligible studies for diagnostic meta-analysis.